Characterisation and relevance of CD138‐negative plasma cells in plasma cell myeloma

Reid, Suzanne J.; Shi, Yang; Brown, R. K. Lee; Kabani, Karieshma; Aklilu, Esther; Ho, P.; Woodland, Narelle; Joshua, Douglas

doi:10.1111/j.1751-553x.2010.01222.x

Cited by 47 publications

(53 citation statements)

References 21 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…17 An in vitro colony assay of CD138 À CD19 À CD34 À cells showed colony formation only in 4/16 (25%) patients which is a lower ratio than the one previously reported (88%) by Matsui et al…”

Section: Consistent With Our Results It Has Been Recently Reported Tcontrasting

confidence: 39%

CD138-negative clonogenic cells are plasma cells but not B cells in some multiple myeloma patients

et al. 2012

View full text Add to dashboard Cite

Section: Consistent With Our Results It Has Been Recently Reported Tcontrasting

confidence: 39%

CD138-negative clonogenic cells are plasma cells but not B cells in some multiple myeloma patients

et al. 2012

View full text Add to dashboard Cite

“…Consequently, circulating PCs are also classified according to the presence or absence of CD138 apart from the maturation based classification of normal PCs mentioned above (27). The circulating CD138 -PCs are thought to be plasma blasts as they express CD45, CD20, CD19 and human leukocyte antigen (hLA)-class II and more actively proliferating (5,47,48) (Fig. 1).…”

Section: Malignant Plasma Cell Characteristicsmentioning

confidence: 99%

“…PCs are prime mediators of the adaptive immune response (5,26). The development of a normal B cell starts in the bone marrow (BM) and matures following migration into the peripheral lymphatic organs.…”

Section: Normal Plasma Cell Characteristicsmentioning

confidence: 99%

“…Amongst the typical markers expressed on PCs, CD45 is considered an early PC marker (plasma blasts) (27). According to the maturation stages, PCs are grouped into plasma blasts (CD138 -CD45 ++ ), early PC's (CD138 + CD45 + ) and mature PC's (CD138 ++ CD45 -or weak CD45 expression) based on the antigen expression on their surface (5).…”

Section: Normal Plasma Cell Characteristicsmentioning

confidence: 99%

“…Multiple myeloma (MM) is the second most prevalent hematological malignancy worldwide, with a median onset of 60 years of age (1)(2)(3)(4)(5)(6). MM is currently incurable, albeit clinically manageable and typically manifests with an accumulation of terminally differentiated monoclonal plasma cells (PCs) in the bone marrow (3).…”

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

Multiple myeloma and persistence of drug resistance in the age of novel drugs (Review)

Krishnan

Jaiswal

Brown

et al. 2016

International Journal of Oncology

View full text Add to dashboard Cite

show abstract

Association of Circulating Antibody‐Secreting Cell Maturity With Disease Features in Primary Sjögren's Syndrome

Steinmetz

Verstappen

Schulz

et al. 2023

Arthritis & Rheumatology

View full text Add to dashboard Cite

Objective B cell hyperactivity plays an important role in primary Sjögren's syndrome (SS). We undertook this study to better understand the B cell effector branch, namely antibody‐secreting cells (ASCs) in primary SS, and to examine the quantity, maturity, and inflammatory properties of ASCs in primary SS patients. Methods Circulating ASCs, defined as CD3–CD14–CD27+CD38++ cells, from 21 primary SS patients and 10 healthy controls were assessed using spectral flow cytometry. Expression levels of relevant ASC markers relating to maturity, survival, and inflammatory status were analyzed using a t‐distributed stochastic neighbor embedding approach. Correlation of ASC properties with primary SS disease parameters was assessed. Results ASCs were more abundant in peripheral blood from primary SS patients than from healthy controls (mean ± SD 3.1 ± 5.1 cells/μl versus 1.1 ± 1.0 cells/μl, respectively; P = 0.048) and displayed a more mature phenotype (mean ± SD CD19– ASCs 0.37 ± 1.21 cells/μl versus 0.06 ± 0.11 cells/μl, respectively; P = 0.005). An inflammatory CXCR3+ phenotype of ASCs correlated positively with our newly developed ASC maturity index (r = 0.568, P = 0.007) but correlated negatively with antiinflammatory interleukin‐10 expression (r = –0.769, P < 0.001). ASCs with a higher maturity index also demonstrated higher levels of the pro‐survival protein myeloid cell leukemia 1 (r = 0.567, P = 0.007). Frequency and/or maturity of ASCs correlated with several primary SS disease parameters, such as antinuclear antibody and anti‐La/SSB titers, salivary gland focus scores, and ocular staining scores. Conclusion Quantity and maturity of ASCs in primary SS patients are increased and correlate with disease parameters. A higher maturity index of ASCs marks a pro‐survival and proinflammatory phenotype. Altogether, B cell hyperactivity in primary SS extends to the peripheral ASC compartment, raising potential for ASCs as future biomarkers or targets for primary SS treatment.

show abstract

Characterisation and relevance of CD138‐negative plasma cells in plasma cell myeloma

Cited by 47 publications

References 21 publications

CD138-negative clonogenic cells are plasma cells but not B cells in some multiple myeloma patients

CD138-negative clonogenic cells are plasma cells but not B cells in some multiple myeloma patients

Multiple myeloma and persistence of drug resistance in the age of novel drugs (Review)

Association of Circulating Antibody‐Secreting Cell Maturity With Disease Features in Primary Sjögren's Syndrome

Contact Info

Product

Resources

About